To date, there have been many studies in HFpEF utilizing novel meds, but very few that exhibited significant benefit in this patient population.
Would anything change this troubling streak?
#CardsJC
Although HFpEF and HFrEF have similarly poor outcomes, HFpEF trials have consistently failed to show a reduction in morbidity and mortality.
Here’s a quick overview of the major HFpEF 📜trials by
@CardioNerds
Academy Fellow
@OAmidiMD
#HouseEinthoven
#CardsJC
Now for
#ELAN
trial!
🔹 Multicenter open label randomized trial
🔹 2013 participants
🔹 Aim ➡️ to evaluate the safety & efficacy of early vs late initiation of DOACs in patients with acute ischemic stroke 🧠 who have atrial fibrillation 🫀
#CardsJC
The patient is rushed to the cath lab. You get access and quickly engage the coronaries to see what you are dealing with.
#CardsJC
❓What do you see in the angiogram? What is the culprit vessel? What do you think about the complexity of the lesions seen?
Join us for the first
@CardioNerds
journal club of ✨2023✨ we'll be discussing ECMO-CS trial!
⏰ Tonight at 8 pm EST
📍
@CardioNerdsJC
#CardsJC
Check out our article summary and visual abstract ⬇️⬇️
Rate vs rhythm control is an old controversy – initial trials found no differences in either strategy w/ regards to MACE, but newer studies reveal benefits for rhythm control.
#CardsJC
❓Any other rate/rhythm control trials that you've based your practice on?
The
@CardioNerds
are back again with a new
#CardsJC
Journal Club!! 🤩🎉
Join us on twitter Thursday🗓️, 7/27/23, 8:00 PM EST🕗in our🔥discussion on the
#ELAN
trial🫀
Get the inside scoop from our experts to help you decide when to start AC💊in your patients with stroke🧠and AF🫀
⛱️
@CardioNerds
is kicking off the 🌞season with a new
#CardsJC
Journal Club. Join us on Twitter this Thursday, 6/29 at 8pm EST. Several experts will join us for a 🔥discussion on the
#RapidHF
trial: this one has something for everyone- from
#HFpEF
to
#EP
! See you there! 🫀🌞🌊
Didn’t have a chance to read CANARY? 🦜
We’ve got you covered!
Check out this awesome visual abstract created by
@DocBrilliant
and reviewed by our chief
@TDonisan
and
#CardsJC
director
@DeveshRaiMD
.
The full-text article can be found here ➡️
Before we get too wrapped up in the
#CardsJC
, please help us give a warm welcome to
@DeveshRaiMD
, who is the new director of the Journal Club for
@CardioNerds
Your clinic patient has chronic, stable coronary artery disease. You've maximized their anti-platelets 🩸, statin 🧡,beta-blocker 💊, but you'd like to reduce their cardiovascular risk further. What can you do?
#CardsJC
It is 2 am. In the midst of your sleep, the pager beeps.
😴📟 – “ED page – STEMI”
You are sent the EKG. How would you like to proceed?
#CardsJC
- Call & get the hx, vitals, & pt’s current status
- Admit to CCU for monitoring/med mgmt
- Go back to sleep, likely false activation
🚨Attention all
@CardioNerds
!!
Join
#HouseTaussig
🫀and a panel of phenomenal experts tomorrow at 8:00 PM EST to discuss the revolutionary results of
#SELECT
🔥
An absolute gamechanger!🤩
Can't wait to see you then! 🕗
It's almost⏲️for this months
#CardsJC
! Come hang out and discuss
#ORBITA2
with this stellar group of nerds.
When: Tomorrow, 2/29, at 8PM EST.
Where: Here!
#CardsJC
We can't wait to 👀you there
The benefits of complete revascularization after a STEMI has been an ongoing topic of trials, with most showing benefits to revascularization in the absence of cardiogenic shock, either w/ FFR or angiographic guidance
#CardsJC
Any other trial worth highlighting?
To get situated: check out this powerful 👊🏼visual abstract crafted by our one and only
@IsaMathiasMD
The full text article can be found at NEJM: 📰
#CardsJC
Enter: SGLT2 inhibitors.
The data has been robust, including for patients with heart failure! But what about HFpEF?
EMPEROR-PRESERVED answered this by evaluating the SGLT2i empagliflozin 10mg daily vs placebo in patients with EF>40%
#CardsJC
But first: check out this amazing visual abstract created by
@AshishCorrea
with review by
@dranulala
.
The full text article can be found at The Lancet: 📰
.
Here is our article summary!
#CardsJC
Didn’t have a chance to read ADVOR? We got you covered. Check out the amazing visual abstract created by
@Gurleen_Kaur96
, with review by chief
@jholtzman3
& director
@DevesRaiMD
. The full text article can be found here:
#CardsJC
And now to discuss our article
#CardsJC
COMPLETE: A multinational, randomized, parallel, comparative effectiveness trial.
Staged non-culprit PCI post STEMI + 💊
Vs
No revascularization of non-culprits + 💊
4041 patients with median follow up of 3 years
Great infographic by
@JuliettePower44PAH
on PAH therapies w/ proven clinical benefits
What is your practice regarding PAH treatment?
PH podcasts
#CardsJC
Didn’t get a chance to read the ARTESIA trial? No worries!
Check out our visual abstract and article summary! Remember to include
#CardsJC
in your tweets.
A BTS pic of the
@CardioNerds
team behind the
#CardsJC
tonight! Everyone involved had a BLAST!
Thank you to all our faculty members,
#FITs
and audience who enriched our discussion!
Terrific time discussing the FAME 3 trial with the
@cardionerds
and
@CardioNerdsJC
backstage! Thank you everyone for tuning in, and look forward to seeing you at the next
#CardsJC
!
Sotatercept (new drug class) w/ distinct mechanism than current therapies. It’s a fusion protein of activin receptor type IIa that traps TGF-B superfamily members rebalancing PA homeostasis
#CardsJC
Didn’t get a chance to read the STELLAR trial? No worries!
Check out our visual abstract and article summary! Remember to include
#CardsJC
in your tweets.
To date, RCTs evaluating different PAH therapies have shown a variable degree of relevant clinical outcomes improvement. The best PAH treatment regimen remains debatable.
#CardsJC
Let’s set the stage! This terrific visual abstract by the talented
@jholtzman3
provides a great overview of the FAME 3 Trial.
The full text article can be found at NEJM: 📰
#CardsJC
#FAME3
Get ready for
@CardioNerds
to discuss STRONG-HF! 💪
@CardioNerdsJC
right here in 30 minutes!
Is rapid up-titration of GDMT before and shortly after discharge from an acute heart failure admission effective and safe?
#CardsJC
#HouseEinthoven
✅ The trial included patients with rapidly deteriorating (
@SCAI
D-E) or severe cardiogenic shock, meeting at least one hemodynamic and metabolic criteria, along with exclusion of hypovolemia.
📚
#CardsJC
Let’s get started with RAPID-HF!
Chronotropic incompetence is common in pts w/ HFpEF & a potential driver of exercise intolerance.
Rate-adaptive pacing is a IIa, expert consensus recommendation for symptom management.
#CardsJC
Before we begin – here is the visual abstract by
@The_Doc_Martin
to get you up to speed!
Link to
@Cardionerds
summary:
The full text article can be found at NEJM: 📰
#CardsJC
Don’t have time to read the full NEJM article? Don’t fret! Check out this rad visual abstract by
@CardioNerds
fellow extraordinaire
@BrainmanM
#CardsJC
It's almost⏲️for this months
#CardsJC
!
Come hang out with us to discuss one of the🔥trials of the year,
#ULTIMATEDAPT
with this stellar group of nerds!
When🕗: Tomorrow 5/9, 8PM EST.
We can't wait to see you there!!
#CardsJC
Didn’t have a chance to read STRONG-HF? We got you covered.
Check out the amazing visual abstract created by
@TySweeney6
, with review by chief
@jholtzman3
&
#CardsJC
director
@DevesRaiMD
.
The full text article can be found here:
Let’s get started! Loop diuretics remain a mainstay of decongestion in acute decompensated heart failure. When do you find yourself reaching for sequential diuretic therapy (e.g. adding on acetazolamide)?
#CardsJC
If you didn’t get a chance to read the original Salt Substitution trial, please check out our visual abstract and article summary!
#CardsJC
#SSaSS
🧂🧂
👀👀Visual abstract by
@HussainMKCards
📜📜Article summary by
@jholtzman3
Let's start with a question re: inclusion criteria.
Patients included in the trial were specifically NOT taking anti-anginals. Why was this important to establish? Does this impact generalizability?
#CardsJC
⚡ Early-rhythm control therapy ⚡ in patients with early AF was associated with ↘️ CV death, stroke, or hospitalization for HF or ACS than usual care (absolute difference in risk, 1.1 events per 100 person-years)
#CardsJC
✨ To get your juices flowing, take a look at this outstanding visual abstract crafted by star fellows
@KarlaAsturias
and
@HanchateShivani
Please click below to see the full-text article:
#CardsJC
❌ No difference between 💊rate and ⚡ rhythm control with regards to:
•Number of nights spent in the hospital (2nd primary outcome)
•Symptoms, quality of life, and LV function at 2 years
•Cognitive function.
❓ Is this result surprising to you?
#CardsJC
We're👩🏼⚕️
@TDonisan
and👨🏻⚕️
@PatrickZakka
,
@CardioNerds
Academy Fellows,
#HouseTaussig
,
We'll be your hosts for this Journal Club, we have no COI.
We want to hear from all of you, so tag your tweets with
#CardsJC
. Introduce yourselves and declare any COI.
Will the
#SELECT
trial change your practice? 🥼
Will you start prescribing GLP-1 agonist to your patients with preexisting CV disease & elevated BMI even without history of diabetes? 💊
#CardsJC
Let’s go to the results!
117 patients were randomized
➡️ Immediate VA-ECMO: 58
➡️ Early conservative therapy: 59
🚨 Cross-over from conservative therapy to VA-ECMO: 39% 🚨
#CardsJC